Collaboration among all providers—surgeon, rheumatologist, physical therapist, etc.—is essential for patients with a rheumatic disease who are about to undergo total joint arthroplasty to reach their goals, including reduced pain and improved mobility…
(Reuters Health)—You might not get what you pay for when it comes to healthcare, a new study hints. A report in Health Affairs on May 2 found little association between how much physician practices charged and patients’ perceptions of their quality of care.1 “We’re asking consumers to make a lot of decisions about healthcare purchasing…
(Reuters Health)—Grating, cracking or popping sounds around joints may predict future arthritis, especially in the knees, according to a recent U.S. study. Among thousands of people with no knee pain who were followed for three years, one quarter had noisy knees yet they made up three quarters of the cases of symptomatic knee arthritis that…
NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases. In a series of studies published in the May 4 New England Journal of Medicine, researchers reported…
On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…
A new formulation of oxycodone in 10 and 15 mg doses is being reviewed by the FDA for treating pain…
The FDA has declined to approve baricitinib to treat rheumatoid arthritis, citing the need for more data on dosing and safety…
NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research….
NKTR-181, a mu-opioid agonist analgesic, has proved safe and effective for treating chronic low back pain vs. placebo in a recent clinical trial…
For patients with rheumatic disease, general treatment guidelines for managing cardiovascular risk are suboptimal, says Katherine Liao, MD. A patient’s level of disease activity and inflammation affect their risk…